147 related articles for article (PubMed ID: 36617999)
1. Cancer-cell-membrane-camouflaged supramolecular self-assembly of antisense oligonucleotide and chemodrug for targeted combination therapy.
Chen T; Xu J; Zhu L; Yan D
Nanoscale; 2023 Jan; 15(4):1914-1924. PubMed ID: 36617999
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Membrane Camouflaged Chemodrug-Gene Nanoparticles for Enhanced Combination Therapy of Ovarian Cancer.
Chen T; Wang Y; Zhu L; Wu J; Lin J; Huang W; Yan D
ACS Appl Mater Interfaces; 2023 Dec; 15(50):58067-58078. PubMed ID: 38056905
[TBL] [Abstract][Full Text] [Related]
3. T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas.
Cheng X; Yu D; Cheng G; Yung BC; Liu Y; Li H; Kang C; Fang X; Tian S; Zhou X; Liu Q; Lee RJ
Mol Pharm; 2018 Oct; 15(10):4722-4732. PubMed ID: 30138565
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
[TBL] [Abstract][Full Text] [Related]
5. Erythrocyte membrane camouflaged siRNA/chemodrug nanoassemblies for cancer combination therapy.
Xu J; Chen T; Sun T; Yu C; Yan D; Zhu L
Biomater Sci; 2022 Nov; 10(22):6601-6613. PubMed ID: 36250610
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
7. Bcl-2 expression in cell lines breast cancer and death program.
Janaghard MS; Soleimani S; Movafagh A; Motallebi M; Mousavi SA; Moghadam AAS; Moghadam VE; Khosravi A; Mirzaei HR; Mousavi SAR; Aziziaram Z; Sun C
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):277-285. PubMed ID: 38279418
[TBL] [Abstract][Full Text] [Related]
8. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
Yip KW; Mocanu JD; Au PY; Sleep GT; Huang D; Busson P; Yeh WC; Gilbert R; O'Sullivan B; Gullane P; Bastianutto C; Liu FF
Clin Cancer Res; 2005 Nov; 11(22):8131-44. PubMed ID: 16299246
[TBL] [Abstract][Full Text] [Related]
9. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
[TBL] [Abstract][Full Text] [Related]
11. Reversing multidrug resistance in Caco-2 by silencing MDR1, MRP1, MRP2, and BCL-2/BCL-xL using liposomal antisense oligonucleotides.
Lo YL; Liu Y
PLoS One; 2014; 9(3):e90180. PubMed ID: 24637737
[TBL] [Abstract][Full Text] [Related]
12. Aptamer-Functionalized DNA Origami for Targeted Codelivery of Antisense Oligonucleotides and Doxorubicin to Enhance Therapy in Drug-Resistant Cancer Cells.
Pan Q; Nie C; Hu Y; Yi J; Liu C; Zhang J; He M; He M; Chen T; Chu X
ACS Appl Mater Interfaces; 2020 Jan; 12(1):400-409. PubMed ID: 31815420
[TBL] [Abstract][Full Text] [Related]
13. Targeting the expression of anti-apoptotic proteins by antisense oligonucleotides.
Delihas N
Curr Drug Targets; 2001 Jun; 2(2):167-80. PubMed ID: 11469717
[TBL] [Abstract][Full Text] [Related]
14. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
[TBL] [Abstract][Full Text] [Related]
15. Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer.
Heger Z; Polanska H; Krizkova S; Balvan J; Raudenska M; Dostalova S; Moulick A; Masarik M; Adam V
Colloids Surf B Biointerfaces; 2017 Feb; 150():131-140. PubMed ID: 27907860
[TBL] [Abstract][Full Text] [Related]
16. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.
Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421
[TBL] [Abstract][Full Text] [Related]
18. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin.
Pakunlu RI; Cook TJ; Minko T
Pharm Res; 2003 Mar; 20(3):351-9. PubMed ID: 12669953
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]